Cognition Therapeutics’ Selected for Support by National Institute on Aging

Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer’s disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH Alzheimer’s Disease Drug […]

Cognition Therapeutics’ Selected for Support by National Institute on Aging Read More »